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Abstract The crystal structure of human immunodeficiency
virus type 1 (HIV-1) protease mutant G48H with peptidic
inhibitor U-89360E is described. Comparison with wild-type
protease-inhibitor complex shows that mutation of flap residue
48 to histidine allows stabilizing van der Waals contacts between
the side chains of His48 and Phe53 as well as between His48 and
the P2P and P3P inhibitor subsites. The flap region is less mobile
than in the wild-type enzyme. A model of saquinavir-resistant
mutant protease G48V in complex with saquinavir predicts
interactions similar to those found in the G48H crystal.
Energetic calculations confirm the similarity of the His48 and
Val48 interactions.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
Therapeutic e¡orts against the human immunode¢ciency
virus type 1 (HIV-1) are handicapped by the development of
drug resistance. The facile mutation and rapid replication of
the virus both contribute to rapid selection of resistant mu-
tants in the presence of inhibitor drugs [1]. Speci¢c mutation
positions in HIV-1 protease are now known to confer in vivo
HIV-1 resistance to several inhibitor drugs [2^4], including
three marketed HIV-1 protease inhibitor drugs: saquinavir
(Ro 31-8959) [5], indinavir (L-735,524) [6], and ritonavir
(ABT-538) [7]. The mutation of Gly48 to valine in HIV-1
protease contributes to viral resistance against sasquinavir
[4]. The kinetics of Gly48 mutants, compared to those of the
wild-type protease, are consistent with the resistant properties
[8^10]. However, the structural basis for these mutation
evoked property changes has not been determined. The struc-
tural changes related to Gly48 mutation are of particular in-
terest because the crystallographic studies of inhibitor-resist-
ant HIV-1 protease mutants have so far dealt with mutations
in substrate binding pockets [11^14]. No structural informa-
tion is available for resistant mutations in the mobile protease
£ap (residues 45 to 55), even though several £ap residues are
mutated in resistant proteases [15].
Here, we describe the crystal structure of the G48H mutant
of HIV-1 protease in complex with a peptidic inhibitor U-
89360E and compare this structure to that of the wild-type
HIV-1 protease bound to the same inhibitor [14]. The study of
a molecular model of saquinavir resistant mutant protease
G48V suggests that the observed structural changes in the
G48H HIV-1 protease are generally applicable to other mu-
tants at this position.
2. Experimental procedures
2.1. Enzyme preparation and crystal growth
The recombinant mutant HIV-1 protease G48H was expressed in E.
coli and puri¢ed as previously described [14] with one modi¢cation.
After refolding, the solution containing the refolded protease was
incubated at 37‡C for 2 h to complete the proteolysis required to
remove extraneous amino acid residues from the protease molecule
[16]. This process was monitored by SDS-polyacrylamide gel electro-
phoresis.
The inhibitor U-89360E was a gift from the Upjohn Co. It is a
derivative of Ac-Phe-Val-Gln-Arg-NH2 in which the peptide bond
between Phe and Val has been replaced by a hydroxyethylene moiety
(-CHOH-CH2-) and the phenyl group has been changed to a cyclo-
hexyl group.
The methods employed in the crystallization experiments were es-
sentially the same as described by Hong et al. [14]. The protein sol-
ution contained 6.5 mg/ml mutant HIV-1 protease in 20 mM sodium
acetate, 1 mM dithiothreitol, pH 5.5, with a 10-fold molar excess of
inhibitor. The reservoir solutions for the vapor di¡usion contained
10% dimethylsulfoxide, 30 mM L-mercaptoethanol and 4% 2-propa-
nol in addition to the precipitant. The most favorable crystallization
conditions were 42% saturated ammonium sulfate, pH 6.8.
2.2. Crystal structure determination
The di¡raction data were collected and reduced as described pre-
viously [14]. The data collection did not record the entire unique
volume of reciprocal space. However, the data recorded was of high
quality so that good re¢nement statistics and clear electron density
maps were obtained (see below). The indexing software suggested an
orthorhombic space group. Systematic absences of re£ections were
consistent with an I centered cell, but the choice between space groups
I222 and I212121 could not be made. Since this is a new crystal form
for HIV-1 protease, the initial phases were determined by molecular
replacement [17], in which a previously determined wild-type HIV-1
protease structure [14] was used as the search model. This calculation
was carried out with the molecular replacement program package
MRCHK [18]. Di¡raction data from resolution 3.6 to 8.0 Aî were
used for both the rotation and translation searches. The correct rota-
tion function solution was 4.2 c above the top noise peak. A trans-
lation function search in space group I222 con¢rmed the rotation
function search and produced a solution 4.1 c above the next highest
peak. Whereas, in space group I212121, no translation function solu-
tion distinguished itself from the background. Consequently, space
group I222 was chosen.
After rigid body and initial positional re¢nement, the R-factor was
0.30 for data from 20.0^2.8 Aî . Electron density showed clear inhibitor
density with only one inhibitor orientation. Water molecules were
added as identi¢ed only if their density exceeded 3 c in the MFoM-
MFcM map and if their position did not produce a violation of van
der Waals radii. Statistics for data collection and re¢nement are sum-
marized in Table 1. Re¢nements of the crystal structure were carried
out using the programs TNT [19] and X-PLOR [20]. Molecular
graphics display and calculation of van der Waals surfaces employed
the program O using default values for van der Waals calculations
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[21]. Since this G48H mutant structure was to be compared to the
wild-type HIV-1 protease structure [14], the latter structure was sub-
jected to several cycles of re¢nement using the TNT and X-PLOR
programs so the observed di¡erences would not be due to idiosyncra-
sies of the re¢nement procedure.
2.3. Modeling for HIV-1 protease mutant G48V complexed to
saquinavir and energetic comparisons
The structural model of HIV-1 protease mutant G48V complexed
to saquinavir was built based on the crystal structure of wild-type
HIV-1 protease complexed to saquinavir [22] obtained from HIV
Protease Structure Data Base [23]. A best ¢t side-chain conformation
of Val48 was selected from the most preferred rotomer library. This
model of the G48V enzyme-saquinavir complex was subjected to en-
ergy minimization calculations using X-PLOR’s conjugate gradient
energy minimization algorithm. Topology and parameter dictionaries
were built for the inhibitor using the bond lengths and angles from the
crystal structure as the ideal values. Harmonic coordinate restraints
were applied to the CK atoms of the enzyme during the minimization.
For both the wild-type and the mutant structures, the binding energies
between saquinavir and each subsite of the protease were calculated
using X-PLOR’s energy functions. To avoid bias generated by the
calculations, the models of the wild-type and mutant enzyme com-
plexes were subjected to the same energy minimization regimens prior
to the binding energy comparison.
3. Results and discussion
3.1. Structure of HIV-1 protease mutant G48H and comparison
to the wild-type enzyme
The structural comparison of G48H and the wild-type HIV-
1 protease (Fig. 1) revealed the most dramatic di¡erence at the
side chain of PheB53. In the structure of the wild-type HIV-1
protease bound to the same inhibitor [14], no van der Waals
contact is present between the side chain of PheB53 and the
rest of the enzyme dimer. In the structure of the G48H mutant
protease, the side chain of PheB53 is at a di¡erent position and
has considerable van der Waals interaction with the mutated
side chain of HisB48 (Fig. 2). Although the positions of PheA53
side chains in the two structures are similar, in the mutant
structure PheA53 side chain is again in van der Waals contacts
with HisA48 as in the B monomer. Additionally, HisB48 favor-
ably interacts with the bound inhibitor at the backbone atoms
in the P2P and P3P subsites and with the L, Q, and N carbon
atoms of the Arg side chain of inhibitor subsite P3P. These
interactions are shown in Fig. 2.
Changes in the positions of main chain atoms were ob-
served at surface locations (Fig. 1). Most changes were at L-
turns but there also was movement at residue 44 in both
monomers (Fig. 1). Although changes of backbone torsion
angles at residues 44 and 45 have been suggested as associated
with £ap opening [24], the currently observed shift does not
cause relocation of the £aps.
3.2. Functional consequences of G48H mutation
The side chains of the £ap residues in the mutant G48H
enzyme are less mobile than the corresponding £ap residues in
the wild-type protease. This is indicated from a comparison of
the crystallographic temperature factors of the main chain
atoms in two structures (Fig. 3). In the wild-type complex,
the B-monomer £ap has less mobility than in the A monomer
as the result of interaction with the inhibitor. Consequently
the change induced by mutation is not so great in B-monomer
(Fig. 3). This increased rigidity in the G48H mutant is most
likely a direct consequence of the interactions between Phe53
and His48 discussed above. The new His48 side chain also
creates a second e¡ect. In the crystal structure, HisB48 side
chain interacts with the P2P and P3P residues of the inhibitor
which is expected to stabilize the complexes between the mu-
tant enzyme to the inhibitor and possibly substrates.
Since the crystal forms are di¡erent in the G48H mutant
and the wild-type enzyme structures, it needs to be established
that the change in thermal parameters is not a consequence of
altered crystal packing. In fact for both £ap regions (A45^A55
and B47^B53) where diminished mobility is seen for the mu-
tant, there are more intermolecular contacts in the wild-type
crystal than in the mutant one. Therefore, the stabilization of
the £ap in the mutant structure occurs even though there is
less constriction by intermolecular contacts than in the wild-
type structure. Additional deviant regions in Fig. 3, viz. A18^
A22, A41^A44, A69^A72, and B18^B22, have thermal param-
eter change as predicted by the number of crystal contacts.
The region A57^A60 which is more rigid in the mutant struc-
ture has no intermolecular contacts in either the mutant or the
wild-type enzyme crystal structures.
The observation that £ap mutation produced structural ri-
gidity contrasts strongly with the observations from previous
crystallographic studies of resistant mutants of HIV-1 pro-
tease, including V82A [11], V82D, V82N [14], A71T/V82A
[12] and a quadruple mutant M46I/L63P/V82T/I84V [13]. In
all these cases, the residue replacements are associated with
substrate side-chain binding sites; these mutations led to
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Table 1
Crystallographic statistics of the wild type and G48H mutant HIV-1 proteases in complex with inhibitor U-89360E
G48H Wild typea
Space group I222 P61
Unit cell (Aî ) a = 58.5, b = 88.2, c = 94.2 a = b = 63.2, c = 83.6
Observed re£ections 25 380 27 072
Unique re£ections 8697 7669
Rsymb 0.073 0.039
Data completeness (%) (20.0^2.3 Aî ) 77.9 90.7
Data completeness (%) (2.42^2.30 Aî ) 52.6 71.7
R-factorc 0.185 0.168
Bond length rms deviation from ideal (Aî ) 0.013 0.013
Bond angle rms deviation from ideal (deg) 1.8 1.8
Number of water molecules 59 78
B-factor (Aî 2) average for protein atoms 36.6 28.1
aData from Hong et al. [14] are included for comparison.
bRsym 
PP
MIih3GIhf=
P
Iih.
cR-factor =
P
MFoM3MFcM=
P
MFoM, where Fo and Fc are the observed and calculated structure factors. The R-factors are reported for the range 8.0
to 2.3 Aî .
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structural changes including gaps or overlaps between van der
Waals spaces of inhibitor and enzyme [11^14] and conforma-
tional adjustments of the mutant enzyme [11,12]. Since the
£aps of the wild-type HIV-1 protease have an unusually
high mobility, the rigidity resulting from the mutation at
Gly48 and possibly other £ap residues is likely a common
phenomenon.
3.3. Structural model of HIV-1 protease mutant
G48V-saquinavir complex and functional implications
The interactions and stabilizing e¡ects described above for
the G48H mutant enzyme are likely present in other Gly48
mutants of HIV-1 protease. A well documented in vivo resist-
ant mutation of HIV-1 protease against saquinavir therapy is
mutant G48V [4]. To further assess the functional e¡ect of
mutation at position 48, a model structure for G48V HIV-1
protease bound to saquinavir was constructed based on the
structure of the wild-type HIV-1 protease in complex with
saquinavir [22]. In this model, the favorable van der Waals
contacts between Phe53 and Val48 and between Val48 and sa-
quinavir are clearly present (Fig. 4). These contacts persisted
in the model throughout the energy minimization cycles.
These new interactions (Fig. 4), which do not occur in the
wild-type HIV-1 protease complexed to saquinavir, should
FEBS 19625 17-12-97 Cyaan Magenta Geel Zwart
Fig. 2. Stereo view of the structural relationship of the inhibitor molecule and protease residues 48A, 53A, 48B and 53B. Electron densities
from the 2MFoM3MFcM map are shown at 1 c contour level. A CK to CK backbone trace for residues 48 to 53 is included. The position of the
side chain of residue B53 in the wild-type structure is also shown (orange).
Fig. 1. Backbone ribbon drawing of G48H HIV-1 protease in complex with the inhibitor U-89360E. Side chains for His48 (yellow) and Phe53
(blue) are shown. The inhibitor molecule (red) within the binding cleft is also depicted. Backbone regions which have signi¢cant positional devi-
ations between the mutant and wild-type enzymes are high-lighted in red.
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have a signi¢cant e¡ect on the properties of the mutant en-
zyme.
It has been argued that the resistant mutation of HIV-1
protease can arise from either the decrease of inhibitor sensi-
tivity or the increase of catalytic e⁄ciency of the mutant en-
zyme [25]. Several £ap mutants of HIV-1 protease are known
to retain a signi¢cant portion of the catalytic capability of the
wild-type enzyme [8,13,26]. For example, the kcat values for
the hydrolysis of a peptide (Val-Ser-Gln-Asn-Tyr/Por-Ile-Val-
Gln) derived from the cleavage site between HIV-1 matrix and
capsid proteins are very close for the wild-type HIV-1 pro-
tease (51.8 s31) and for G48V mutant protease (31.4 s31) [10].
For some substrates, the kcat/Km is even greater for several
Gly48 mutants, including G48H (Lin et al., 1995) and G48V
mutant proteases [10], than for the wild-type enzyme. The
similarity between the interactions of G48H enzyme (Fig. 2)
and the G48V enzyme (Fig. 4) suggests that the decrease of
£ap mobility and the additional favorable interactions be-
tween the mutant enzyme and the substrates most likely con-
tribute to the preserving of catalytic activity.
A relatively small 13.5-fold increase of Ki for the G48V
mutant HIV-1 protease compared to that of the wild-type
enzyme contributes favorably to the saquinavir resistance
[10]. Current structural models provide an opportunity to
critically evaluate the interactions of inhibitors with the
Gly48 mutant enzymes and with the wild-type HIV-1 protease.
In order to better de¢ne and quantify binding interactions in
the crystal structures and models, the van der Waals binding
energies and total binding energies were calculated from the
structures for the following enzyme-inhibitor pairs: G48H
mutant enzyme bound to inhibitor U-89360E, G48V mutant
enzyme bound to saquinavir, and the wild-type HIV-1 pro-
tease bound separately to each of these two inhibitors. For the
G48H mutant complex, van der Waals binding interactions to
inhibitor U-89360E are more favorable than those in the wild-
type enzyme bound to the same inhibitor (Fig. 5A). The dif-
ferences are primarily attributable to the new interactions dis-
cussed above between the inhibitor and residues of the pro-
tease £ap. This additional stabilization of mutant enzyme-
inhibitor complex by van der Waals interactions does not
carry through to the free energy of binding, since the Kis
for the U-89360E are 119 nM for G48H and 20 nM for the
wild-type protease [8]. The X-PLOR calculations indicate that
the destabilizing factor in the G48H protease-inhibitor com-
plex is relatively unfavorable electrostatic interactions for the
Arg side chain of the U-89360E inhibitor to the mutant en-
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Fig. 3. Average main-chain thermal parameter di¡erence between G48H and wild-type protease. After normalization of wild-type thermal pa-
rameters to those of the G48H mutant, the mean crystallographic thermal parameter for each residue in the wild-type enzyme complex is sub-
tracted from that of the G48H mutant. Panels A and B are for the A and B monomers of the HIV-1 protease, respectively. The residues within
the £ap (45^55) are identi¢ed and fall well below the zero line.
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zyme. The aggregate van der Waals interaction of G48V HIV-
1 protease with saquinavir is nearly identical to that in the
wild-type protease-saquinavir complex (Fig. 5B). The total
binding energy calculated by X-PLOR is less favorable for
the G48V complex with saquinavir than for the wild-type
protease complex (Fig. 5B). The predominant di¡erence be-
tween these complexes is an electrostatic destabilization in the
mutant complex especially in the P1 subsite of saquinavir. The
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Fig. 4. Van der Waals interaction of PheA53, ValA48 and the P3 subsite of saquinavir in the structural model of HIV-1 mutant protease G48V
complex with saquinavir. The saquinavir positions in the wild-type crystal structure (orange) and of the G48V mutant model structure (yellow)
are both shown. There is a 30‡ rotation of the saquinavir P3 planar quinoline group (double ring) in the G48V complex compared to that in
the wild-type enzyme. This change appears to be a result of its interaction with Val48. The van der Waals interaction between Val48 and Phe53
is shown but the view does not minimize overlap of the surfaces.
Fig. 5. Comparison of van der Waals and total binding energies. Van der Waals (VDW) and total binding energy (Total) are shown for the in-
teraction of the inhibitor with the wild-type HIV-1 protease (WT), the mutant protease, the £ap residues (45^55) of the WT and mutant pro-
tease. A: Energy is evaluated for the re¢ned crystal structures of G48H and wild-type HIV-1 protease bound to U-89360E. B: Energy is eval-
uated for the models of G48V and wild-type HIV-1 protease bound to saquinavir after energy minimization.
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greater binding energy calculated for the wild-type complex
than for the G48V mutant is consistent with the free energy of
binding. The Kis for saquinavir inhibition of wild-type HIV-1
protease and the G48V mutant are 0.2 and 2.7 nM, respec-
tively [10]. These energetic comparisons illustrate an interest-
ing point. Even though the new G48 side chains interact sim-
ilarly with other enzyme groups and inhibitors as shown in
Fig. 2 Fig. 5, these interactions have di¡erent impact on the
total van der Waals binding energy of inhibitors.
From the crystal structure, the model building experiment
and the energetic calculations, one is able to conclude that the
interaction between Phe53 and a mutant side chain at residue
48 is probably a general structural feature of Gly48 mutants of
HIV-1 protease. Total binding energy is not a direct conse-
quence of the productive van der Waals interactions visible in
crystal structures. For U-89360E, van der Waals interactions
with the G48H mutant are more favorable than for the wild-
type protease. There seems to be no net change in the van der
Waals energy for saquinavir binding to the G48V mutant
compared to the wild-type protease. For both comparisons
made herein, the total binding energy is less for inhibitor
binding to the mutant protease than to the wild-type protease
(Fig. 5).
The structural observations detailed above may be applica-
ble to other mutations in the HIV-1 protease £ap. In the
molecular dynamics modeling studies of Collins et al. [24],
the M46I mutant demonstrated noticeably less £ap £exibility
than the wild-type HIV-1 protease. Moreover, the simian im-
munode¢ciency virus protease is homologous to HIV-1 pro-
tease except that residue 46 is isoleucine. In the structure of
that protease in complex with an inhibitor, Phe53 makes van
der Waals contact with Ile46 [27]. This provides yet another
example of stabilizing interactions between Phe53 and side
chains at either position 46 or 48 in these mutant proteases.
We suggest that this is a usual case for mutations in the £ap
region of HIV-1 protease.
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